Literature DB >> 20492006

Initiation and duration of proton pump inhibitors in the Australian veteran population.

S V Gadzhanova1, E E Roughead, J M Mackson.   

Abstract

AIM: To determine the duration of initial treatment with high strength proton pump inhibitors prescribed for gastro-oesophageal reflux disease in the veteran population in Australia and variance by the medical professional who initiated treatment.
METHOD: Retrospective cohort study in the Australian veteran population using Department of Veterans' Affairs pharmacy claims data. Veterans who had been dispensed at least one prescription for the high strength proton pump inhibitor indicative of gastro-oesophageal reflux disease between 1 July 2004 and 30 June 2007, were eligible for full health services, and who had not been dispensed any proton pump inhibitor in the previous 12 months were included in the study. The study end-point was time to discontinuation of initial high strength proton pump inhibitor (cessation or switch to maintenance strength) stratified by the type of initial prescriber.
RESULTS: Of the new users of high strength proton pump inhibitors (n= 41 041), 32% discontinued within 8 weeks, and 62% discontinued within 12 months. The median treatment duration was: 195 days (95% CI, 186-205) for patients with hospital-initiated therapy (n= 12 294), 124 days (95% CI, 121-127) for patients with treatment initiated by general practitioners (n= 25 327) and 112 days (95% CI, 104-121) for patients with treatment initiated by specialist (n= 3420).
CONCLUSIONS: Only one-third of the Australian veteran patients who initiated high strength proton pump inhibitor treatment for gastro-oesophageal reflux disease discontinued (ceased or stepped down) within 8 weeks consistent with guideline recommendations. The majority continued treatment beyond recommended durations. This is not directly attributable to the initiating prescriber.
© 2010 The Authors. Internal Medicine Journal © 2010 Royal Australasian College of Physicians.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20492006     DOI: 10.1111/j.1445-5994.2010.02259.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  6 in total

Review 1.  Effectiveness of Interventions to Deprescribe Inappropriate Proton Pump Inhibitors in Older Adults.

Authors:  Tom D Wilsdon; Ivanka Hendrix; Tilenka R J Thynne; Arduino A Mangoni
Journal:  Drugs Aging       Date:  2017-04       Impact factor: 3.923

2.  Concomitant use of SSRIs, NSAIDs/aspirin and gastroprotective drugs among residents of long-term care facilities: a medical record review.

Authors:  J Simon Bell; Heidi T Taipale; Helena Soini; Kaisu H Pitkälä
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

3.  Proton pump inhibitor prescriptions and subsequent use in US veterans diagnosed with gastroesophageal reflux disease.

Authors:  Andrew J Gawron; John E Pandolfino; Scott Miskevics; Sherri L Lavela
Journal:  J Gen Intern Med       Date:  2013-07       Impact factor: 5.128

4.  Proton pump inhibitors and the risk of pneumonia: a comparison of cohort and self-controlled case series designs.

Authors:  Emmae N Ramsay; Nicole L Pratt; Philip Ryan; Elizabeth E Roughead
Journal:  BMC Med Res Methodol       Date:  2013-06-24       Impact factor: 4.615

Review 5.  Deprescribing versus continuation of chronic proton pump inhibitor use in adults.

Authors:  Taline A Boghossian; Farah Joy Rashid; Wade Thompson; Vivian Welch; Paul Moayyedi; Carlos Rojas-Fernandez; Kevin Pottie; Barbara Farrell
Journal:  Cochrane Database Syst Rev       Date:  2017-03-16

6.  Passing the acid test? Evaluating the impact of national education initiatives to reduce proton pump inhibitor use in Australia.

Authors:  Claudia Bruno; Sallie-Anne Pearson; Benjamin Daniels; Nicholas A Buckley; Andrea Schaffer; Helga Zoega
Journal:  BMJ Qual Saf       Date:  2019-10-22       Impact factor: 7.035

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.